Loading...
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Ciuleanu, T Ahmed, S Kim, J Mezger, J Park, K Thomas, M Chen, J Poondru, S VanTornout, J Whitcomb, D
Ciuleanu, T
Ahmed, S
Kim, J
Mezger, J
Park, K
Thomas, M
Chen, J
Poondru, S
VanTornout, J
Whitcomb, D
Citations
Altmetric:
Abstract
Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pathways mediate resistance to individual receptor blockade. This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients with NSCLC.
Description
Date
2017-09-05
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 219.99 KB
Keywords
Type
Article
Citation
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. 2017, 117 (6):757-766 Br J Cancer